These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 16417211)

  • 1. Inhibition of pemphigus vulgaris by targeting of the CD40-CD154 co-stimulatory pathway: a step toward antigen-specific therapy?
    Liu Z; Li N; Diaz LA
    J Invest Dermatol; 2006 Jan; 126(1):11-3. PubMed ID: 16417211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerance induction by the blockade of CD40/CD154 interaction in pemphigus vulgaris mouse model.
    Aoki-Ota M; Kinoshita M; Ota T; Tsunoda K; Iwasaki T; Tanaka S; Koyasu S; Nishikawa T; Amagai M
    J Invest Dermatol; 2006 Jan; 126(1):105-13. PubMed ID: 16417225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40/CD154 interactions at the interface of tolerance and immunity.
    Quezada SA; Jarvinen LZ; Lind EF; Noelle RJ
    Annu Rev Immunol; 2004; 22():307-28. PubMed ID: 15032580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway.
    Toubi E; Shoenfeld Y
    Autoimmunity; 2004; 37(6-7):457-64. PubMed ID: 15621572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease.
    Howard LM; Miller SD
    Autoimmunity; 2004 Aug; 37(5):411-8. PubMed ID: 15621565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges.
    Law CL; Grewal IS
    Adv Exp Med Biol; 2009; 647():8-36. PubMed ID: 19760064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of the CD154-CD40 costimulatory pathway prevents the development of experimental autoimmune glomerulonephritis.
    Reynolds J; Khan SB; Allen AR; Benjamin CD; Pusey CD
    Kidney Int; 2004 Oct; 66(4):1444-52. PubMed ID: 15458437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costimulatory molecule CD154 in systemic lupus erythematosus and rheumatoid arthritis. Therapeutic perspectives.
    Dejica DI; Manea EM
    Roum Arch Microbiol Immunol; 2006; 65(1-2):66-74. PubMed ID: 17877113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis.
    Engel D; Seijkens T; Poggi M; Sanati M; Thevissen L; Beckers L; Wijnands E; Lievens D; Lutgens E
    Semin Immunol; 2009 Oct; 21(5):308-12. PubMed ID: 19616449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge.
    Ferrant JL; Benjamin CD; Cutler AH; Kalled SL; Hsu YM; Garber EA; Hess DM; Shapiro RI; Kenyon NS; Harlan DM; Kirk AD; Burkly LC; Taylor FR
    Int Immunol; 2004 Nov; 16(11):1583-94. PubMed ID: 15466914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated CD154/CD40L and CD40 on peripheral blood T and B lymphocytes.
    Meabed MH; Taha GM; Mohamed SO; El-Hadidy KS
    Hematology; 2007 Aug; 12(4):301-7. PubMed ID: 17654056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Blockade of CD40/CD154 signal as a therapeutic strategy for autoimmune diseases].
    Kuwana M
    Nihon Rinsho Meneki Gakkai Kaishi; 2003 Oct; 26(5):259-66. PubMed ID: 14635399
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of CD86/CD28 and CD40/CD154 pathways in regulating monocyte-derived CD80 expression during their interaction with allogeneic endothelium.
    Wang P; Liu Z; Wu C; Zhu B; Wang Y; Xu H
    Transplant Proc; 2008 Oct; 40(8):2729-33. PubMed ID: 18929847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD154-CD40 interactions are essential for thymus-dependent antibody production in zebrafish: insights into the origin of costimulatory pathway in helper T cell-regulated adaptive immunity in early vertebrates.
    Gong YF; Xiang LX; Shao JZ
    J Immunol; 2009 Jun; 182(12):7749-62. PubMed ID: 19494299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
    Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
    Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks.
    Gares SL; Fischer KP; Congly SE; Lacoste S; Addison WR; Tyrrell DL; Gutfreund KS
    Clin Vaccine Immunol; 2006 Aug; 13(8):958-65. PubMed ID: 16893998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of the number of CD154 molecules in membrane extracts used as a source of CD40 stimulation of human B lymphocytes.
    Ducas E; Dussault N; Roy A; Dumont N; Néron S
    J Immunol Methods; 2009 May; 344(2):133-7. PubMed ID: 19332074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of CD40-CD154 costimulatory pathway promotes survival of allogeneic corneal transplants.
    Qian Y; Boisgerault F; Benichou G; Dana MR
    Invest Ophthalmol Vis Sci; 2001 Apr; 42(5):987-94. PubMed ID: 11274076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Is it possible to treat diseases by manipulation of lymphocytes?].
    Ogasawara K
    Rinsho Byori; 2001 Dec; 49(12):1225-32. PubMed ID: 11797392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD40-expressing carcinoma cells induce down-regulation of CD40 ligand (CD154) and impair T-cell functions.
    Batrla R; Linnebacher M; Rudy W; Stumm S; Wallwiener D; Gückel B
    Cancer Res; 2002 Apr; 62(7):2052-7. PubMed ID: 11929824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.